Clinical characteristics, therapies and the number of patients who needed intensive care unit and mechanical ventilation in patients with and without COVID-19 atypical lymphocytes (COVID-19 LY) circulating in peripheral blood (n=36)
| Patients with COVID-19 LY n=18 | Patients without COVID-19 LY n=18 | |||
| Age (years) | 53 (30–88) | 74 (46–90) | ||
| Sex | Men | 13 (72%) | 11 (61%) | |
| Women | 5 (28%) | 7 (39%) | ||
| Symptoms | Fever | 18 (100%) | 16 (89%) | |
| Cough | 13 (72%) | 14 (78%) | ||
| Dyspnoea | 10 (56%) | 9 (50%) | ||
| Nausea | 0 (0%) | 2 (11%) | ||
| Vomiting | 0 (0%) | 2 (11%) | ||
| Diarrhoea | 1 (6%) | 1 (6%) | ||
| Myalgia | 3 (17%) | 2 (11%) | ||
| Dysgeusia | 4 (22%) | 0 (0%) | ||
| Anosmia | 4 (22%) | 0 (0%) | ||
| Death | 0 (0%) | 4 (22%) | ||
| Drugs | Antibiotic therapy | 17 (94%) | 18 (100%) | |
| Antiviral therapy | 16 (89%) | 16 (89%) | ||
| Antiparasitic therapy | 17 (94%) | 17 (94%) | ||
| Antifungal therapy | 0 (0%) | 1 (6%) | ||
| Immunosuppression | Tocilizumab | 3 (17%) | 7 (39%) | |
| Tocilizumab+Anakinra | 2 (11%) | 2 (11%) | ||
| Tocilizumab+Dexamethasone | 1 (5%) | |||
| Siltuximab | 1 (5%) | |||
| Anakinra | 1 (5%) | |||
| Intensive care unit | Yes | 1 (6%) | 9 (50%) | |
| No | 17 (94%) | 9 (50%) | ||
| Mechanical ventilation | Yes | 1 (6%) | 8 (44%) | |
| No | 17 (94%) | 10 (56%) | ||